

Takayuki Ikezoe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6156008/publications.pdf>

Version: 2024-02-01

106
papers

1,936
citations

257450

24
h-index

289244

40
g-index

111
all docs

111
docs citations

111
times ranked

2801
citing authors

#	ARTICLE	IF	CITATIONS
1	Mitochondrial STAT3 exacerbates LPS-induced sepsis by driving CPT1a-mediated fatty acid oxidation. <i>Theranostics</i> , 2022, 12, 976-998.	10.0	37
2	Long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: post-marketing surveillance in Japan. <i>International Journal of Hematology</i> , 2022, 115, 470-480.	1.6	4
3	A phase II randomized study evaluating azacitidine versus conventional care regimens in newly diagnosed elderly Japanese patients with unfavorable acute myeloid leukemia. <i>International Journal of Hematology</i> , 2022, , 1.	1.6	1
4	The suppressive effects of Mer inhibition on inflammatory responses in the pathogenesis of LPS-induced ALI/ARDS. <i>Science Signaling</i> , 2022, 15, eabd2533.	3.6	12
5	A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: One-year results. <i>Genetics in Medicine</i> , 2022, 24, 1425-1436.	2.4	30
6	Prognostic value of plasma high mobility group box 1 protein and histone H3 levels in patients with disseminated intravascular coagulation: a multicenter prospective cohort study. <i>Thrombosis Journal</i> , 2022, 20, .	2.1	3
7	Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies. <i>International Journal of Hematology</i> , 2021, 113, 34-44.	1.6	24
8	<i>Aurka</i> loss in CD19 ⁺ B cells promotes megakaryocytopoiesis via IL-6/STAT3 signaling-mediated thrombopoietin production. <i>Theranostics</i> , 2021, 11, 4655-4671.	10.0	3
9	Targeting HLA-F suppresses the proliferation of glioma cells via a reduction in hexokinase 2-dependent glycolysis. <i>International Journal of Biological Sciences</i> , 2021, 17, 1263-1276.	6.4	11
10	Simultaneous silencing Aurora-A and UHRF1 inhibits colorectal cancer cell growth through regulating expression of DNMT1 and STAT1. <i>International Journal of Medical Sciences</i> , 2021, 18, 3437-3451.	2.5	3
11	Diagnosis and treatment of disseminated intravascular coagulation in COVID-19 patients: a scoping review. <i>International Journal of Hematology</i> , 2021, 113, 320-329.	1.6	7
12	Hypofibrinogenemia is associated with a high degree of risk in infectious diseases: a post-hoc analysis of post-marketing surveillance of patients with disseminated intravascular coagulation treated with thrombomodulin alfa. <i>Thrombosis Journal</i> , 2021, 19, 12.	2.1	8
13	Myeloproliferative neoplasm-driving Calr frameshift promotes the development of pulmonary hypertension in mice. <i>Journal of Hematology and Oncology</i> , 2021, 14, 52.	17.0	4
14	A Case of Acquired von Willebrand Syndrome Complicated by Acute Myelomonocytic Leukemia. <i>Case Reports in Oncology</i> , 2021, 14, 1152-1158.	0.7	1
15	An evaluation of the Japanese Society on Thrombosis and Hemostasis criteria for disseminated intravascular coagulation as a predictor of prognosis in patients with infection. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1566-1574.	1.3	4
16	Heterogeneity in the diagnosis of plasmablastic lymphoma, plasmablastic myeloma, and plasmablastic neoplasm: a scoping review. <i>International Journal of Hematology</i> , 2021, 114, 639-652.	1.6	5
17	Dasatinib induces endothelial-to-mesenchymal transition in human vascular-endothelial cells: counteracted by cotreatment with bosutinib. <i>International Journal of Hematology</i> , 2021, 113, 441-455.	1.6	4
18	<i>Aurka</i> deficiency in the intestinal epithelium promotes age-induced obesity via propionate-mediated AKT activation. <i>International Journal of Biological Sciences</i> , 2021, 17, 1302-1314.	6.4	6

#	ARTICLE	IF	CITATIONS
19	Weight Loss Intervention before Cord Blood Transplantation in an Obese Patient with Acute Myeloid Leukemia: A Case Study. <i>Progress in Rehabilitation Medicine</i> , 2021, 6, n/a.	0.9	0
20	SOS/TA-TMA. <i>Journal of Illusion</i> , 2021, 10, 136-144.	0.1	0
21	Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial. <i>Blood</i> , 2021, 138, 3601-3601.	1.4	0
22	Normal B Cell-Derived iPSCs Capable of Inducing RAS Mutants and Aid to Explore Myeloma-Initiating Cells. <i>Blood</i> , 2021, 138, 4711-4711.	1.4	0
23	Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e902-e911.	4.6	30
24	The link between interleukin-1 β and acute myocardial infarction in chronic myeloid leukemia patients treated with nilotinib: cross-sectional study. <i>Annals of Hematology</i> , 2020, 99, 359-361.	1.8	3
25	Circulating intranuclear proteins may play a role in development of disseminated intravascular coagulation in individuals with acute leukemia. <i>International Journal of Hematology</i> , 2020, 111, 378-387.	1.6	9
26	Treatment of T-Cell Prolymphocytic Leukemia with Central Nervous System Involvement Using Intrathecal Alemtuzumab Administration. <i>Case Reports in Hematology</i> , 2020, 2020, 1-4.	0.4	3
27	Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients. <i>International Journal of Hematology</i> , 2020, 112, 466-476.	1.6	5
28	Assessment of dysplasia in bone marrow smear with convolutional neural network. <i>Scientific Reports</i> , 2020, 10, 14734.	3.3	18
29	Possibility of cancer-stem-cell-targeted radioimmunotherapy for acute myelogenous leukemia using 211At-CXCR4 monoclonal antibody. <i>Scientific Reports</i> , 2020, 10, 6810.	3.3	14
30	Inhibition of Aurora-A Promotes CD8+ T-Cell Infiltration by Mediating IL10 Production in Cancer Cells. <i>Molecular Cancer Research</i> , 2020, 18, 1589-1602.	3.4	13
31	Optimal timing of apheresis for the efficient mobilization of peripheral blood progenitor cells recruited by high-dose granulocyte colony-stimulating factor in healthy donors. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102737.	1.0	7
32	Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e218-e225.	4.6	65
33	Analysis of the association between resolution of disseminated intravascular coagulation (DIC) and treatment outcomes in post-marketing surveillance of thrombomodulin alpha for DIC with infectious disease and with hematological malignancy by organ failure. <i>Thrombosis Journal</i> , 2020, 18, 2.	2.1	13
34	JAK2V617F Mutation Promoted IL-6 Production and Glycolysis via Mediating PKM1 Stabilization in Macrophages. <i>Frontiers in Immunology</i> , 2020, 11, 589048.	4.8	6
35	Diagnosis of Bleeding Tendency and Treatment Based on the Pathological Condition. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2020, 109, 1337-1339.	0.0	0
36	Clinical effects of recombinant thrombomodulin and defibrotide on sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 674-680.	2.4	18

#	ARTICLE	IF	CITATIONS
37	A critical role of the Gas6-Mer axis in endothelial dysfunction contributing to TA-TMA associated with GVHD. <i>Blood Advances</i> , 2019, 3, 2128-2143.	5.2	13
38	Introduction of Chromosomal Translocation t(11; 14) and a p53 Deletion into Normal B Cell-Derived iPSCs to Elucidate the Cellular Origin of Myeloma Cells. <i>Blood</i> , 2019, 134, 3057-3057.	1.4	0
39	Knock-Ins of Type-2 Calr Mutants Cause Myeloproliferative Neoplasm (MPN)-like Hematopoiesis in Mice. <i>Blood</i> , 2019, 134, 2964-2964.	1.4	0
40	Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan. <i>International Journal of Hematology</i> , 2018, 107, 656-665.	1.6	19
41	Defibrotide Stimulates Angiogenesis and Protects Endothelial Cells from Calcineurin Inhibitor-Induced Apoptosis via Upregulation of AKT/Bcl-xL. <i>Thrombosis and Haemostasis</i> , 2018, 118, 161-173.	3.4	13
42	Independent Paroxysmal Nocturnal Hemoglobinuria and Myelodysplastic Syndrome Clones in a Patient With Complete Bone Marrow Failure. <i>HemaSphere</i> , 2018, 2, e142.	2.7	0
43	miR-217 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitors by targeting pro-oncogenic anterior gradient 2. <i>Experimental Hematology</i> , 2018, 68, 80-88.e2.	0.4	18
44	Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease. <i>Internal Medicine</i> , 2018, 57, 3651-3657.	0.7	4
45	Cytoprotective and pro-angiogenic functions of thrombomodulin are preserved in the C loop of the fifth epidermal growth factor-like domain. <i>Haematologica</i> , 2018, 103, 1730-1740.	3.5	12
46	HMGA2 mRNA Expression in Patients with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN). <i>Blood</i> , 2018, 132, 4384-4384.	1.4	0
47	Autocrine and Paracrine Interactions between Multiple Myeloma Cells and Bone Marrow Stromal Cells by Growth Arrest-specific Gene 6 Cross-talk with Interleukin-6. <i>Journal of Biological Chemistry</i> , 2017, 292, 4280-4292.	3.4	27
48	The Fifth Epidermal Growth Factor-like Region of Thrombomodulin Alleviates Murine Graft-versus-Host Disease in a G-Protein Coupled Receptor 15 Dependent Manner. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 746-756.	2.0	24
49	MicroRNA-9 plays a role in interleukin-10-mediated expression of E-cadherin in acute myelogenous leukemia cells. <i>Cancer Science</i> , 2017, 108, 685-695.	3.9	19
50	G-protein coupled receptor 15 mediates angiogenesis and cytoprotective function of thrombomodulin. <i>Scientific Reports</i> , 2017, 7, 692.	3.3	21
51	The BCR/ABL tyrosine kinase inhibitor, nilotinib, stimulates expression of IL-1 β in vascular endothelium in association with downregulation of miR-3p. <i>Leukemia Research</i> , 2017, 58, 83-90.	0.8	26
52	A possible role of low regulatory T cells in anti-acetylcholine receptor antibody positive myasthenia gravis after bone marrow transplantation. <i>BMC Neurology</i> , 2017, 17, 93.	1.8	4
53	In vitro studies on the role of recombinant human soluble thrombomodulin in the context of retinoic acid mediated APL differentiation syndrome. <i>Leukemia Research</i> , 2017, 63, 1-9.	0.8	4
54	Steroid-resistant autoimmune myelofibrosis in a patient with autoimmune hepatitis and Evans syndrome complicated with increased expression of TGF- β 2 in the bone marrow: a case report. <i>International Journal of Hematology</i> , 2017, 106, 718-724.	1.6	3

#	ARTICLE	IF	CITATIONS
55	The fifth epidermal growth factor like region of thrombomodulin alleviates LPS-induced sepsis through interacting with GPR15. <i>Thrombosis and Haemostasis</i> , 2017, 117, 570-579.	3.4	20
56	The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a <i>JAK2</i> Exon 12 Mutation. <i>Internal Medicine</i> , 2017, 56, 1705-1710.	0.7	2
57	Relationship between HMGB1 and PAI-1 after allogeneic hematopoietic stem cell transplantation. <i>Journal of Blood Medicine</i> , 2016, 7, 1.	1.7	10
58	Digital necrosis associated with chronic cold haemagglutinin disease. <i>British Journal of Haematology</i> , 2016, 174, 343-343.	2.5	2
59	BCR/ABL increases EZH2 levels which regulates XIAP expression via miRNA-219 in chronic myeloid leukemia cells. <i>Leukemia Research</i> , 2016, 45, 24-32.	0.8	20
60	Inhibition of IRE1 \pm -driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 18736-18749.	1.8	71
61	HMGA2 Orchestrates the Tumorigenesis of Myeloproliferative Neoplasms (MPN) in Corporation with <i>JAK2V617F</i> . <i>Blood</i> , 2016, 128, 796-796.	1.4	0
62	Autocrine and Paracrine Interactions Between Multiple Myeloma Cells and Bone Marrow Stromal Cells By Growth Arrest-Specific Gene 6 Crosstalk with Interleukin-6. <i>Blood</i> , 2016, 128, 5606-5606.	1.4	0
63	Blockade of CD 82 by a monoclonal antibody potentiates anti-leukemia effects of AraC <i>in vivo</i> . <i>Cancer Medicine</i> , 2015, 4, 1426-1431.	2.8	8
64	STAT5A regulates DNMT3A in CD34 ⁺ /CD38 ⁺ AML cells. <i>Leukemia Research</i> , 2015, 39, 897-905.	0.8	12
65	Thrombomodulin/activated protein C system in septic disseminated intravascular coagulation. <i>Journal of Intensive Care</i> , 2015, 3, 1.	2.9	102
66	Disseminated intravascular coagulation in non-Hodgkin lymphoma. <i>International Journal of Hematology</i> , 2015, 102, 413-419.	1.6	10
67	Tetraspanin Family Member, CD82, Regulates Expression of EZH2 via Inactivation of p38 MAPK Signaling in Leukemia Cells. <i>PLoS ONE</i> , 2015, 10, e0125017.	2.5	16
68	Downregulation of miR-217 correlates with resistance of <i>ph</i> ⁺ leukemia cells to <i>scp</i> ABL tyrosine kinase inhibitors. <i>Cancer Science</i> , 2014, 105, 297-307.	3.9	54
69	Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin. <i>International Journal of Hematology</i> , 2014, 100, 27-37.	1.6	64
70	CD82 regulates STAT5/IL-10 and supports survival of acute myelogenous leukemia cells. <i>International Journal of Cancer</i> , 2014, 134, 55-64.	5.1	29
71	Over-expression of Mcl-1 impairs the ability of ATRA to induce growth arrest and differentiation in acute promyelocytic leukemia cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2013, 18, 1403-1415.	4.9	10
72	CD34 ⁺ /CD38 ⁺ acute myelogenous leukemia cells aberrantly express CD82 which regulates adhesion and survival of leukemia stem cells. <i>International Journal of Cancer</i> , 2013, 132, 2006-2019.	5.1	38

#	ARTICLE	IF	CITATIONS
73	Effect of recombinant human soluble thrombomodulin on clinical outcomes of patients with coagulopathy after hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2013, 91, 442-447.	2.2	16
74	Effect Of Recombinant Human Soluble Thrombomodulin On Clinical Outcomes Of patients With Coagulopathy After Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 4803-4803.	1.4	0
75	Recombinant Thrombomodulin For The Treatment Of Transplantation-Associated Coagulopathy After Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 5454-5454.	1.4	0
76	Beneficial Effect Of Anticoagulants In The Management Of Patients With Acute Promyelocytic Leukemia (APL): Results Of a Multicenter, Retrospective Epidemiologic Study Of The Disseminated Intravascular Coagulation Patients In Japan. <i>Blood</i> , 2013, 122, 2373-2373.	1.4	1
77	Thrombomodulin Protects Endothelial Cells From a Calcineurin Inhibitor-Induced Cytotoxicity by Upregulation of Extracellular Signal-Regulated Kinase/Myeloid Leukemia Cell-1 Signaling. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 2259-2270.	2.4	54
78	Recombinant human soluble thrombomodulin safely and effectively rescues acute promyelocytic leukemia patients from disseminated intravascular coagulation. <i>Leukemia Research</i> , 2012, 36, 1398-1402.	0.8	41
79	Thrombomodulin enhances the antifibrinolytic and antileukemic effects of all-trans retinoic acid in acute promyelocytic leukemia cells. <i>Experimental Hematology</i> , 2012, 40, 457-465.	0.4	20
80	Recombinant Human Soluble Thrombomodulin Safely and Effectively Rescues Acute Promyelocytic Leukemia Patients From Disseminated Intravascular Coagulation.. <i>Blood</i> , 2012, 120, 2226-2226.	1.4	0
81	CD82 Regulates STAT5/IL-10 and Supports Survival of Acute Myelogenous Leukemia Cells.. <i>Blood</i> , 2012, 120, 2981-2981.	1.4	3
82	STAT5A Regulates DNMT3 and Inactivates PTEN Tumor Suppressor Gene in CD34+/CD38 ⁻ AML Cells. <i>Blood</i> , 2012, 120, 4087-4087.	1.4	0
83	Diffuse alveolar hemorrhage associated with lenalidomide. <i>International Journal of Hematology</i> , 2011, 93, 830-831.	1.6	12
84	Inhibition of signal transducer and activator of transcription 5 by the inhibitor of janus kinases stimulates dormant human leukemia CD34+/CD38 ⁻ cells and sensitizes them to antileukemia agents. <i>International Journal of Cancer</i> , 2011, 128, 2317-2325.	5.1	21
85	Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia. <i>International Journal of Cancer</i> , 2011, 129, 2512-2521.	5.1	40
86	CD34+/CD38 ⁻ Acute Myelogenous Leukemia Cells Aberrantly Express Aurora Kinase A. <i>Blood</i> , 2011, 118, 1886-1886.	1.4	0
87	p53 is critical for the Aurora B kinase inhibitor-mediated apoptosis in acute myelogenous leukemia cells. <i>International Journal of Hematology</i> , 2010, 91, 69-77.	1.6	28
88	Recombinant Human Soluble Thrombomodulin Enhances the Anti-Fibrinolytic and Anti-Leukemia Effects of All-Trans Retinoic Acid In Acute Promyelocytic Leukemia Cells.. <i>Blood</i> , 2010, 116, 1079-1079.	1.4	16
89	CD34+/CD38 ⁻ Leukemia Stem Cells Aberrantly Express CD82 Adhesion Molecule. <i>Blood</i> , 2010, 116, 2168-2168.	1.4	0
90	Analysis of Aurora B kinase in non-Hodgkin lymphoma. <i>Laboratory Investigation</i> , 2009, 89, 1364-1373.	3.7	36

#	ARTICLE	IF	CITATIONS
91	Analysis of Aurora B Kinase in Non-Hodgkin's Lymphoma.. Blood, 2008, 112, 1610-1610.	1.4	3
92	Blockade of mTOR Signaling Potentiates the Ability of Histone Deacetylase Inhibitor to Induce Growth Arrest and Differentiation of Acute Myelogenous Leukemia Cells.. Blood, 2008, 112, 1612-1612.	1.4	0
93	A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia. Molecular Cancer Therapeutics, 2007, 6, 1851-1857.	4.1	122
94	Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Leukemia Research, 2007, 31, 673-682.	0.8	95
95	Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: Enhancement of growth inhibition via inhibition of 3-kinase/Akt/mammalian target of rapamycin signaling. Cancer Science, 2006, 97, 945-951.	3.9	52
96	HIV-1 protease inhibitor ritonavir potentiates the effect of 1,25-dihydroxyvitamin D3 to induce growth arrest and differentiation of human myeloid leukemia cells via down-regulation of CYP24. Leukemia Research, 2006, 30, 1005-1011.	0.8	24
97	The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Molecular Cancer Therapeutics, 2006, 5, 2522-2530.	4.1	100
98	ZM447439, a Novel Aurora Kinase Inhibitor, Induces Growth Arrest and Apoptosis of Human Leukemia Cells.. Blood, 2006, 108, 1990-1990.	1.4	2
99	PC-SPES down-regulates COX-2 via inhibition of NF-kappaB and C/EBPbeta in non-small cell lung cancer cells. International Journal of Oncology, 2006, 29, 453-61.	3.3	6
100	CCAAT/Enhancer-Binding Protein β : A Molecular Target of 1,25-Dihydroxyvitamin D3 in Androgen-Responsive Prostate Cancer LNCaP Cells. Cancer Research, 2005, 65, 4762-4768.	0.9	51
101	The Anti-Tumor Effects of SU11248, a Class III Receptor Tyrosine Kinase Inhibitor, Against a Variety of Human Hematological Malignancies.. Blood, 2005, 106, 2795-2795.	1.4	1
102	Insulin-like growth factor binding protein-3 antagonizes the effects of retinoids in myeloid leukemia cells. Blood, 2004, 104, 237-242.	1.4	69
103	C/EBP β Modulates Cell Growth, Differentiation and Apoptosis of Myeloid Leukemia, Prostate and Breast Cancer Cells.. Blood, 2004, 104, 4300-4300.	1.4	8
104	HIV-1 Protease Inhibitor Ritonavir Potentiates the Effect of 1,25-Dihydroxyvitamin D3 to Induce Growth Arrest and Differentiation of Human Myeloid Leukemia Cells Via Inhibition of CYP24.. Blood, 2004, 104, 2543-2543.	1.4	25
105	PC-SPES: A Potent Inhibitor of Nuclear Factor- κ B Rescues Mice from Lipopolysaccharide-Induced Septic Shock. Molecular Pharmacology, 2003, 64, 1521-1529.	2.3	39
106	PC-SPES: Molecular mechanism to induce apoptosis and down-regulate expression of PSA in LNCaP human prostate cancer cells. International Journal of Oncology, 2003, 23, 1461-70.	3.3	3